Deslorelin
Phase 2Small molecule
Deslorelin is one of 51 small molecule programs targeting Precocious Puberty. It is currently in Phase 2.
3
Indications
3
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tykerb
GSKPreclinical
Tecentriq
RochePreclinical
Prolia
AmgenPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Deslorelin
EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 2
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Acupan
YYonsei University
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Short stature1 trial
Breast Cancer1 trial
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
Active, not recruiting·—·Phase 2·NCT00080756·11 enrolled
Precocious Puberty1 trial
Treatment of Boys With Precocious Puberty
Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00001202·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Deslorelin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details